Iron chelation therapy with deferasirox results in improvement of liver enzyme level in patients with iron overload-associated liver dysfunction

Yasuo Miura, Yusuke Matsui, Hitomi Kaneko, Mitsumasa Watanabe, Mitsuru Tsudo

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Iron chelation therapy (ICT) has been applied for the patients with iron overload-associated liver dysfunction since it is one of the causes of death in patients with intractable hematological diseases requiring multiple red blood cell transfusions. Recently, deferasirox (DSX), a novel, once-daily oral iron chelator, was demonstrated to have similar efficacy to the conventional continuous infusion of deferoxamine on a decrease in serum ferritin (SF) level in heavily transfused patients. We show three cases of transfusion-mediated iron-overloaded patients with an elevated serum alanine aminotransaminase (ALT). All three patients who received the ICT with DSX showed a decrease in ALT level in association with a decrease in SF level. It is suggested that DSX therapy could be considered to expect the improvement of liver damage for iron-overloaded patients with an abnormal ALT level.

Original languageEnglish
Article number675060
JournalCase Reports in Medicine
Volume2010
DOIs
Publication statusPublished - 2010

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Fingerprint Dive into the research topics of 'Iron chelation therapy with deferasirox results in improvement of liver enzyme level in patients with iron overload-associated liver dysfunction'. Together they form a unique fingerprint.

  • Cite this